KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) FCF Margin (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of FCF Margin readings, the most recent being 41386.72% for Q4 2025.

  • On a quarterly basis, FCF Margin rose 4139035.0% to 41386.72% in Q4 2025 year-over-year; TTM through Dec 2025 was 73.94%, a 8548.0% increase, with the full-year FY2025 number at 39.64%, up 5118.0% from a year prior.
  • FCF Margin hit 41386.72% in Q4 2025 for Biocryst Pharmaceuticals, up from 25.74% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 41386.72% in Q4 2025 to a low of 320.64% in Q1 2021.
  • Median FCF Margin over the past 5 years was 27.36% (2022), compared with a mean of 2023.12%.
  • Biggest five-year swings in FCF Margin: surged 420bps in 2024 and later soared 4139035bps in 2025.
  • Biocryst Pharmaceuticals' FCF Margin stood at 71.18% in 2021, then surged by 57bps to 30.64% in 2022, then surged by 74bps to 7.82% in 2023, then skyrocketed by 54bps to 3.62% in 2024, then soared by 1142787bps to 41386.72% in 2025.
  • The last three reported values for FCF Margin were 41386.72% (Q4 2025), 25.74% (Q3 2025), and 24.72% (Q2 2025) per Business Quant data.